| Literature DB >> 35651977 |
Yue Zhuo1, Meng Li2, Qiyao Jiang1, Hanzhong Ke3, Qingchun Liang4, Ling-Feng Zeng5, Jiansong Fang1.
Abstract
Osteoporosis (OP) is a systemic metabolic skeletal disease which can lead to reduction in bone mass and increased risk of bone fracture due to the microstructural degradation. Traditional Chinese medicine (TCM) has been applied in the prevention and treatment of osteoporosis for a long time. Terpenoids, a class of natural products that are rich in TCM, have been widely studied for their therapeutic efficacy on bone resorption, osteogenesis, and concomitant inflammation. Terpenoids can be classified in four categories by structures, monoterpenoids, sesquiterpenoids, diterpenoids, and triterpenoids. In this review, we comprehensively summarize all the currently known TCM-derived terpenoids in the treatment of OP. In addition, we discuss the possible mechanistic-of-actions of all four category terpenoids in anti-OP and assess their therapeutic potential for OP treatment.Entities:
Keywords: osteoblast; osteoclast; osteoporosis; terpenoids; traditional Chinese medicine
Mesh:
Substances:
Year: 2022 PMID: 35651977 PMCID: PMC9150774 DOI: 10.3389/fendo.2022.901545
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 6.055
Figure 1Chemical structures of natural monoterpenoids, sesquiterpenoids and diterpenoids from TCM.
Figure 2Chemical structures of natural triterpenes from TCM.
Figure 3Schematic of anti-osteoporosis mechanisms of terpenoid on osteoblasts and osteoclasts. The activation of MAPK, PI3K/Akt, Wnt/β-catenin signaling pathways and so on, or inhibition of NF-κB and RANKL/RANK signaling pathways, can promote cell proliferation or differentiation in osteoblasts, which benefits osteoporosis treatment. Meanwhile, the inhibition of MAPK, NF-κB, RANKL/RANK, and NFATc1 signaling pathways, or activation of PI3K/Akt and Nrf2 signaling pathways, also exerts potential therapeutic efficacy via regulating osteoclasts. Some terpenoids, such as andrographolide and tanshinone IIA, show anti-osteoporosis effect by modifying multi-targets. Arrows (↓) indicate activation of a factor or positive effect on indicated cell type, while inverted T marks (⊥) indicate inhibition or negative effect. Subclass of terpenoids is distinguished with different colors: monoterpenoids (red), sesquiterpenoids (yellow), diterpenoids (blue), and triterpenoids (green).
Summary of studies for the antiosteoporotic effects of natural terpenoids from natural Chinese medicine.
| Category | Compound | TCM | Cells/ | Mechanism | Reference |
|---|---|---|---|---|---|
| Monoterpenoids | Sweroside |
| Human osteosarcoma cell line (SaOS-2); OVX mice | Induced the mineralization of bone matrix | ( |
| Human MG-63 cells; Rat OBs | Promoted differentiation and inhibited apoptosis | ( | |||
| MC3T3-E1 cells | Activated p38 signaling pathway | ( | |||
| BMSCs; OVX mouse | Hyperactivated the mTORC1/PS6 signaling pathway | ( | |||
| Swertiamarin |
| Rat fibroblast-like synoviocytes (FLS) | Inhibited caspase 3, TNFa, IL-6, PGE2, COX-2, iNOS, MMPs, p38 MAPKa and modulated RANKL | ( | |
| RAW 264.7 macrophage cells | Inhibited NF-κB/IκB and JAK2/STAT3 signaling | ( | |||
| C57/BL6J BMCs; Sprague Dawley rat neonates OBs; Freund’s Complete Adjuvant induced rat arthritis | Inhibited RANKL/RANK; promoted OPG signaling | ( | |||
| Monotropein |
| MC3T3-E1 cell line; Female osteoporotic C57/BL6 mice | Blocked NF-κB pathway; Enhanced bone formation and blocked increased secretion of inflammatory cytokines | ( | |
| Primary OBs | Prevented Akt/mTOR signaling pathway | ( | |||
| MC3T3-E1 cells; OVX C57/BL6 mice | Inhibited sRANKL signaling | ( | |||
| Catalpol |
| BMMs; RAW264.7 cells; C57BL/6 mice | Suppressed NF-κB and AKT signaling pathways | ( | |
| BMSCs; Male Sprague-Dawley rats | Activated Wnt/β-catenin pathway. | ( | |||
| BMSCs; SD female rats | Activated JAK2/STAT3 axis | ( | |||
| MC3T3-E1 cells; Male ICR mice | Inhibited bone resorption | ( | |||
| Paeoniflorin |
| MC3T3-E1 cells | Enhanced glyoxalase system and inhibited the glycation | ( | |
| Mice BM cells; Mice OC; RAW 264.7 cells; Male DBA/1 mice; Male C57/BL6 mice | Suppressed NF-κB signaling pathway | ( | |||
| Mouse BMMs; OVX C57BL/6 mice | Inhibited NF-κB signaling pathway | ( | |||
| Murine osteoblastic MC3T3-E1 cells | Activated PI3K signaling pathway | ( | |||
| Albiflorin | MC3T3-E1 cells | Suppressed oxidative damage through protecting cytochrome c and cardiolipin | ( | ||
| MC3T3-E1 cells; Sprague Dawley rats femoral fractures | Activated BMP-2/Smad and Wnt/β-catenin pathway | ( | |||
| Bakuchiol |
| Primary human OBs; OVX rats Sprague-Dawley rats | Up-regulated the Wnt signalling pathway | ( | |
| MCF-7 cells; OVX Sprague–Dawley rats | Increased alkaline phosphatase, Ca concentrations, serum E2 concentration and bone mineral density, and decreased the inorganic P level | ( | |||
| Primary mouse OC precursor cells; Bone marrow cells | Inhibited AKT and AP-1 pathways | ( | |||
| Sesquiterpenoid | Costunolide |
| Murine OB MC3T3-E1 cells | Activated PI3K signaling pathway | ( |
| Mice BMCs | Suppressed RANKL-mediated c-Fos transcriptional activity | ( | |||
| Dehydrocostus lactone | Mice BMMs, BMSCs, RAW264.7 cells; OVX C57BL/6J mice | Suppressed NF-κB and NFAT signaling pathways | ( | ||
| Mice BMMs; Male C57BL/6 mice | Modulated NF‐κB signalling pathway | ( | |||
| RAW264.7 cells, Mice BMMs (C57BL/6 male mice) | Inhibiting NF-κB and AP-1 pathways | ( | |||
| Mice BMMs; OVX C57BL/6 female mice | Down-regulated the integrin b3, PKC-b, and Atg5 expression | ( | |||
| Diterpenoids | Euphorbia factor L1 |
| Mouse BMMs; C57BL/6 male mice | Attenuated c-Fos expression and NF-κB activation; activated Nrf2 signaling pathway | ( |
| Abietic acid |
| RAW 264.7 cell line; Mice BMMs; C57/BL6 male mice | Inhibited NF-KB and MAPK signaling | ( | |
| Andrographolide |
| BMSC; SD rat | Activated wnt/β-catenin signaling pathway | ( | |
| Mouse BMMs; RAW 264.7 cells; OVX C57BL/6 mice | Suppressed RANKL signaling pathways | ( | |||
| MC3T3-E1 cell; OVX Sprague Dawley rats | Up-regulated the OPG/RANKL signaling pathway | ( | |||
| Mouse BMSCs; OVX Sprague Dawley rats | Inhibited the NF-kB signaling pathway | ( | |||
| Mouse BMM Cells; C57/BL6 mice | Attenuated NF-κB and ERK/MAPK signalling pathways | ( | |||
| Carnosic acid |
| RAW 264.7 cells; Mouse BMMs; C57BL/6 male mice | Activated the Nrf2 and suppressed the NF-κB pathways | ( | |
| RAW 264.7 cells; Mouse BMMs; Female C57BJ/6L mice | Dual-targeting of sterol regulatory element-binding protein 2 and ERRα | ( | |||
| Crocin |
| RAW264.7 cells | Regulated glyoxalase, oxidative stress, and mitochondrial function | ( | |
| Mice BMMs; Murine macrophage cell line; RAW264.7 cells | Suppressed NF- B signaling pathway | ( | |||
| Kirenol |
| Mouse BMMs; OVX C57BL/6 mice | Inhibited Cav-1, NFATc1 and the related NF-κB/MAPKs/c-Fos signaling pathways | ( | |
| MC3T3-E1 cells | Activated the BMP and Wnt/β-catenin signaling pathways | ( | |||
| Tanshinone IIA |
| Human embryonic kidney (HEK) 293 cells; C57BL/6 mice | Inhibited renin activity | ( | |
| Mice osteoblasts; Female Wnt1sw/sw mice | Up-regulated the NF-κB signaling pathway | ( | |||
| Tanshinone VI | Mice BMMCs; RAW-264.7 cells; C57BL/6 mice | Suppresed the NF-κB, PI3-kinase/Akt, and MAPK pathways, as well as the transcription factor NFATc1 | ( | ||
| Mice bone marrow cells; Male ICR mice. | Inhibited the expression of c-Fos and NFATc1 | ( | |||
| OCs | Inhibited RANKL expression and NFkB induction | ( | |||
| Triptolide |
| Male Sprague-Dawley rats | Down-regulated RANKL and up-regulated OPG | ( | |
| RAW 264.7 (mouse macrophage) | Inhibited NF-kB activation, inhibited IkBa kinase activation, IkBa phosphorylation, and IkBa degradation | ( | |||
| RAW 264.7 cells; Mice BMMCs; Female C57BL/6 mice | Inhibited PI3K-AKT-NFATc1 pathway | ( | |||
| Oridonin |
| Mouse BMMs; MC3T3-E1 cells; Female C57BL/J6 mice(OVX mice) | Inhibited IκB phosphorylation and Ifrd1 degradation | ( | |
| Mouse BMSCs; Mouse BMMs; SD rats | Activated Wnt/β-catenin signaling pathway, down-regulated RANKL and up-regulated OPG expression | ( | |||
| Triterpenoids | Lupeol |
| UMR-106 cell; Female Wistar albino rats | Inhibited MAPK, NF- κB, NFATc1, and c-Fos | ( |
| Alisol B 24-acetate |
| Mast cells; Balb/c mice, ICR mice | Released Syk-mediated down-stream signals including PLC, ERK, and p38 MAPK, NF-κB, cPLA2, COX-2, and Ca2+, | ( | |
| Alisol B | OBs; Bone marrow cells; ddY mice; C57BL/6J (B6) (wild-type) mice | Inhibit NFATc1 and c-Fos signaling pathway | ( | ||
| Alisol C 23-acetate | Calvaria osteoblastic cell; OCs; OVX rat | Inhibited RANKL-induced osteoclast differentiation and function | ( | ||
| Alisol A 24-acetate | Mouse BMCs; BMMs | Downregulated NFATc1 | ( | ||
| Oleanolic acid |
| Cell Counting Kit-8 (CCK-8); Mouse BMMs; OVX C57BL/6 mice | Inhibited the expression of NFATc1 and suppressed the expression of MMP9, Ctsk, TRAP and Car2 | ( | |
| RAW264.7 cells | Inhibited RANKL-induced osteoclastogenesis | ( | |||
| Ursolic acid |
| Mouse osteoblastic MC3T3-E1 subclone 4 cells | Activated MAP kinases and NF-κB signaling pathway | ( | |
| Glycyrrhizic acid |
| Male Sprague–Dawley rats | Inhibited the 11β-hydroxysteroid dehydrogenase type 1 enzyme (11β-HSD1) | ( | |
| RAW264.7 cell; Mouse BMMs; C57BL/6/Bkl mice (OVX mouse) | Suppressed NF-κB, ERK, and JNK pathway | ( | |||
| RAW264.7 cells; Mouse BMMs;OVX C57BL/6J mice | Inactivated NF-κB signaling. | ( | |||
| Male CSF1r-eGFP-KI mice and their wild type strain C57BL/6 | Diminished the size of inflammatory osteolysis | ( | |||
| Glycyrrhetinic Acid | Mouse BMMs; RAW264.7 cells; OVX C57BL/6 female mice | Inhibited NF-κB and MAPK signaling pathways. | ( | ||
| Ginsenoside Rg1 |
| Human dental pulp stem cells (hDPSCs); BMSCs; OCs | Promoted the proliferation and differentiation of DPSCs into odontoblast-like cells by promoted the expression of anti-osteoporosis related genes | ( | |
| Betulinic Acid |
| Mouse BMMs; Female C57BL/6 mice; OVX mice | Inhibited MAPK and NFATc1 signaling pathways | ( | |
| MC3T3-E1 OBs | Activated BMP/Smad/Runx2 and β-catenin signal pathways | ( | |||
| Limonin |
| OC-like cell model | Inhibited bone resorption and reduced the number of multinucleated cells | ( | |
| MC3T3-E1 cell line | Promoted the p38-MAPK signaling | ( | |||
| Nomilin |
| Mouse BMMs; Mouse RAW 264.7 | Suppressed NFATc1 and MAPK signaling pathways | ( | |
| Diosgenin |
| OVX rats | Decreased the RANKL/OPG ratio | ( | |
| Dioscin | Mouse BMMs cells; RAW264.7 cells; LPS- induced bone loss mouse | inhibiting the Akt signaling pathway | ( | ||
| MC3T3-E1 cells and MG-63 cells | Promoted osteoblasts proliferation and differentiation | ( | |||
| Ophiopogonin D |
| OBs MC3T3-E1 cell; RAW264.7 cells; OVX mouse | Reducted oxidative stress | ( | |
| Endothelium-specific Klf3 knockout mice | Inhibited Krüppel-like factor 3 (KLF3) | ( | |||
| Cycloastragenol |
| MC3T3-E1 cells | Activated telomerase | ( | |
| Hederagenin |
| Mice BMMs; OVX mice | Inhibited RANKL-induced bone resorption and OC generation, activated MAPK signaling pathway (ERK and p38) | ( | |
| Tubeimoside I |
| Mice BMMs; RAW 264.7 cells; Male SD rats | Down-regulated NF-κB signaling pathway | ( |